Orchestra BioMed Holdings Inc Ordinary Shares OBIO 深 滬
已收盤 08-01 16:00:00 美东时间
2.44
-0.620
-20.26%
華盛通- 最 高2.75
- 今 開2.70
- 成交量 172.19万股
- 最 低 2.44
- 昨 收 3.06
- 總市值 9348.25万
- 52周最高 7.04
- 市盈率 靜 --
- 換手率 4.49%
- 52周最低 2.37
- 委 比 -87.68%
- 總股本 3831.25万
- 歷史最高 23.39
- 量 比 8.60
- 振 幅 10.13%
- 歷史最低 2.37
- 每 手 1
- 風險率 1.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Orchestra BioMed Secures $70M for Cardiology Programs
Orchestra BioMed Holdings ( ($OBIO) ) has issued an update. On July 31, 2025, O...
08-01 04:49
Orchestra BioMed Announces Proposed Public Offering; No Size Or Amount Disclosed
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that
08-01 04:03
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
Orchestra BioMed announced it has secured $70 million in new capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. Ligand will invest $40 million, including a $15 million equity private placement, for royalties on future sales of Orchestra’s AVIM therapy and Virtue SAB. Medtronic will invest $30 million, with $10 million in equity and $20 million in a secured subordinated promissory note convertible to a...
07-31 20:01
Orchestra BioMed Confirms Director Elections and Auditor
Orchestra BioMed Holdings ( ($OBIO) ) has issued an update. On June 24, 2025, O...
06-25 04:28
Orchestra BioMed Holdings Presents Key Clinical Insights Into Role Of AVIM Therapy For Treatment Of High-Risk Hypertension At Congenital, Structural, And Valvular Heart Disease Interventions 2025 Meeting
Presentation underscores unique potential for atrioventricular interval modulation ("AVIM") therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to
06-18 21:32
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
Orchestra BioMed presented AVIM therapy's potential to manage hypertension in high-risk patients, particularly those with diastolic dysfunction and HFpEF. AVIM therapy, compatible with dual-chamber pacemakers, aims to lower blood pressure by reducing cardiac preload and modulating autonomic nervous system responses. The therapy has received FDA Breakthrough Device Designation and is being evaluated in the BACKBEAT pivotal study, in collaboration ...
06-18 13:30
Orchestra BioMed shares are trading higher after the company reported better-than-expected Q1 sales results.
Orchestra BioMed shares are trading higher after the company reported better-th...
05-14 01:49
Orchestra BioMed Hldgs Q1 EPS $(0.49) Misses $(0.48) Estimate, Sales $868.00K Beat $575.80K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 28.95 percent decrease over losses of $(0.38) per
05-13 04:58
Orchestra BioMed Receives FDA Approval for IDE Amendment
Orchestra BioMed Holdings ( ($OBIO) ) just unveiled an update. On April 22, 202...
04-29 21:54
